Sanofi and AstraZeneca’s Beyfortus (Nirsevimab) is now approved by the National Pharmaceutical Regulatory Agency (NPRA) and ...

In the latest close session, Astrazeneca (AZN) was up +1.93% at $91.56. The stock's change was more than the S&P 500's daily loss of 0.16%. Elsewhere, the Dow lost 0.09%, while the tech-heavy Nasdaq ...

The FDA's approval is based on results from the Phase III DESTINY-Breast09 trial, in which the combo showed a median 40.7-month progression-free survival.

Food and Drug ​Administration has approved ‌Daiichi Sankyo's therapy in combination ‌with Roche's drug for the first-line ...

After AstraZeneca and Daiichi Sankyo made waves in June with eye-opening results for Enhertu in a combination treatment for a ...

RAD51-based assessment effectively identifies HER2-negative metastatic breast cancer patients likely to respond to olaparib, especially with BRCA1/2 or PALB2 variants. RAD51-low tumors showed a higher ...

England has embraced degree apprenticeship as a solution to a wide range of challenges, including high youth unemployment, spiraling student debt and rapid technological change. The programs have been ...

In this video, Brian T. Hill, MD, PhD, discusses data from the Smart Stop trial assessing the effects of a novel targeted combination therapy in patients with newly diagnosed diffuse large B-cell ...

AstraZeneca ($AZN) announced an update on their ongoing clinical study. AstraZeneca recently completed a clinical study titled ‘A Multiple Centre, ...

Steve Eisman is a hedge-fund trader best known on Wall Street for successfully betting against the housing market before the recession of 2007-09. His experiences in the lead-up to the financial ...

President Donald Trump just announced deals with drugmakers Eli Lilly and Novo Nordisk that will yield lower prices for GLP-1 ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...